CBL Protein

CBL proto-oncogene acts as a RING finger E3 ubiquitin ligase, transfers ubiquitin from specific E2 ubiquitin-conjugating enzymes to targeting substrates for degradation by the proteasome(1). The N-terminal phosphotyrosine binding domain of CBL allows the interaction with the substrates containing phosphorylated tyrosine including the activated receptor tyrosine kinases, which plays the negative regulation of these pathways (1). Mutation or translocation of CBL is involved in acute myeloid leukemia, Jacobsen syndrome and Noonan syndrome-like disorder (2, 3).